{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (2026 Q2)",
      "prediction": "BEAT",
      "answer": "pred ~$0.95 vs. cons $0.93",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic revenue growth (2026 Q2)",
      "prediction": "BEAT",
      "answer": "pred ~4.0% vs. cons 3.5%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Unit case volume growth (2026 Q2)",
      "prediction": "MISS",
      "answer": "pred ~1.0% vs. cons 1.5%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Comparable EPS growth guidance (FY2026)",
      "prediction": "LOWER",
      "answer": "guide ~8.0% vs. cons 8.5% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic revenue growth guidance (FY2026)",
      "prediction": "UNCHANGED",
      "answer": "guide ~4.5% vs. cons 4.5% (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Fairlife disruption impact on organic revenue",
      "prediction": "LOWER",
      "answer": "guide ~-0.5% vs. cons -0.2% (2026 H2)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -1.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -2.7,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A modest Q2 operating beat is likely outweighed by softer volume and Fairlife-related second-half caution; implicit out-period cuts should pull FY2026 and FY2027 estimates lower after the report.",
  "day5_confidence": "MEDIUM"
}